Showing results (611-620 of 667) with videos related to

Sort By:
Pageof 67
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2023
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenibC Serrano, S Bauer, D Gómez-Peregrina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyE Ben-Ami, C M Barysauskas, M von Mehren, et al.
Blood|January 18, 2003
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoAnne-Marie O'Farrell, Tinya J Abrams, Helene A Yuen, et al.
British Journal of Cancer|February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Molecular Cancer Therapeutics|July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage StrategyThomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
The Oncologist|July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyJohn R Zalcberg, Michael C Heinrich, Suzanne George, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
Pageof 67